Alembic Pharmaceuticals Limited (NSE:APLLTD) informed stock exchanges on 4th August 2026 that its Board of Directors approved the consolidated and standalone unaudited financial results for the quarter ended 30th June 2026, with the statutory auditors issuing an unqualified limited review report.
Key Highlights
- Consolidated revenue from operations for Q1 FY27 stood at Rs 2,149.77 crore, up from Rs 1,710.72 crore in Q1 FY26, reflecting year-on-year growth of approximately 25.6%.
- Consolidated profit before tax for Q1 FY27 was Rs 221.86 crore, compared with Rs 190.10 crore in Q1 FY26, with no exceptional items reported in the current quarter.
- Standalone revenue from operations for Q1 FY27 was Rs 1,868.06 crore, against Rs 1,494.17 crore in Q1 FY26, with a standalone profit before tax of Rs 255.90 crore.
- The statutory auditors' limited review report for both consolidated and standalone results is unqualified, as disclosed in the filing.
About the Company
Alembic Pharmaceuticals Limited (NSE:APLLTD), headquartered at Alembic Road, Vadodara, Gujarat, is engaged solely in the pharmaceuticals business. The company manufactures and markets branded generics, generic formulations, and active pharmaceutical ingredients, serving both domestic and international markets, including regulated markets such as the United States. Its CIN is L24230GJ2010PLC061123.
Announcement in Detail
The Board meeting commenced at 12:00 noon and concluded at 1:55 p.m. on 4th August 2026. On a consolidated basis, total income for Q1 FY27 was Rs 2,164.70 crore. Total expenses were Rs 1,943.23 crore, yielding a profit before exceptional items and tax of Rs 221.86 crore. The consolidated operating margin (EBITDA before exceptional items) was 16.18% for Q1 FY27, compared with 13.84% in Q1 FY26. The consolidated debt-equity ratio stood at 0.28 times as of 30th June 2026.
On a standalone basis, total income for Q1 FY27 was Rs 1,882.10 crore, with total expenses of Rs 1,626.19 crore and profit before tax of Rs 255.90 crore. The standalone operating margin was 19.26% for the quarter. The standalone net worth as of 30th June 2026 was Rs 5,819.40 crore, and the standalone debt-equity ratio was 0.20 times. The company operates in a single reportable segment, as stated in the filing.
Impact on Investors
The filing shows both consolidated and standalone profitability improved on a year-on-year basis in Q1 FY27, with no exceptional items recognised in the current quarter. Investors will note that the prior quarter ended 31st March 2026 included exceptional charges of Rs 24.76 crore relating to employee benefit obligations under revised Labour Codes and a write-down on the Sikkim manufacturing facility, making direct sequential profit comparisons less straightforward.
Shareholders will observe that the consolidated debt-equity ratio of 0.28 times and current ratio of 1.75 times indicate a moderately leveraged balance sheet. The statutory auditors' report being unqualified for both sets of results is a compliance-positive disclosure, as noted in the filing.
Sector / Market Context
India's pharmaceutical industry remains one of the largest globally by volume, with the domestic formulations market and regulated export markets, particularly the United States, being key revenue drivers for mid-to-large Indian pharma companies. According to Pharmaceuticals Export Promotion Council of India data, Indian pharma exports have been on a sustained growth trajectory, providing a broad backdrop to Alembic Pharmaceuticals' reported revenue increase.